Finanzen von Prime Medicine, Inc (PRME)PRMEPrime Medicine, Inc

Evaluating the bottom line, Prime Medicine, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3750.87%, while the net margin is -3648.96%. These profitability ratios, combined with a Return on Equity (ROE) of -373.29%, provide a clear picture of how effectively PRME converts its operational activities into shareholder value.

In the context of the broader market, PRME competes directly with industry leaders such as ATTO and CADL. With a market capitalization of $694.67M, it holds a leading position in the sector. When comparing efficiency, PRME's gross margin of 100.00% stands against ATTO's 100.00% and CADL's N/A. Such benchmarking helps identify whether Prime Medicine, Inc. is trading at a premium or discount relative to its financial performance.

Despite significant net losses, Prime Medicine has maintained a gross margin of 100% across recent quarters, indicating strong potential for profitability once revenues increase.